144 related articles for article (PubMed ID: 22948869)
1. Comparison of fluconazole renal penetration levels in healthy and Candida albicans-infected Wistar rats.
Azeredo FJ; de Araújo BV; Haas SE; Torres B; Pigatto M; de Andrade C; Dalla Costa T
Antimicrob Agents Chemother; 2012 Nov; 56(11):5852-7. PubMed ID: 22948869
[TBL] [Abstract][Full Text] [Related]
2. Free renal levels of voriconazole determined by microdialysis in healthy and Candida sp.-infected Wistar rats.
de Araujo BV; da Silva CF; Haas SE; Dalla Costa T
Int J Antimicrob Agents; 2009 Feb; 33(2):154-9. PubMed ID: 19010646
[TBL] [Abstract][Full Text] [Related]
3. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model.
Andes D; van Ogtrop M
Antimicrob Agents Chemother; 1999 Sep; 43(9):2116-20. PubMed ID: 10471550
[TBL] [Abstract][Full Text] [Related]
4. In Vivo Microdialysis To Determine Subcutaneous Interstitial Fluid Penetration and Pharmacokinetics of Fluconazole in Intensive Care Unit Patients with Sepsis.
Sinnollareddy MG; Roberts MS; Lipman J; Lassig-Smith M; Starr T; Robertson T; Peake SL; Roberts JA
Antimicrob Agents Chemother; 2016 Feb; 60(2):827-32. PubMed ID: 26596947
[TBL] [Abstract][Full Text] [Related]
5. Fluconazole distribution in rat dermis following intravenous and topical application: a microdialysis study.
Mathy FX; Ntivunwa D; Verbeeck RK; Préat V
J Pharm Sci; 2005 Apr; 94(4):770-80. PubMed ID: 15729707
[TBL] [Abstract][Full Text] [Related]
6. The ability of fluconazole to penetrate into ventilated, healthy and inflamed lung tissue in a model of severe sepsis in rats.
Mauric O; Thallinger C; Kugler SA; Joukhadar SM; Kovar FM; Konz KH; Graninger W; Joukhadar C
Pharmacology; 2011; 87(3-4):130-4. PubMed ID: 21502769
[TBL] [Abstract][Full Text] [Related]
7. Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans.
Louie A; Banerjee P; Drusano GL; Shayegani M; Miller MH
Antimicrob Agents Chemother; 1999 Dec; 43(12):2841-7. PubMed ID: 10582869
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.
Debruyne D
Clin Pharmacokinet; 1997 Jul; 33(1):52-77. PubMed ID: 9250423
[TBL] [Abstract][Full Text] [Related]
9. Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans.
Marchetti O; Entenza JM; Sanglard D; Bille J; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 2000 Nov; 44(11):2932-8. PubMed ID: 11036003
[TBL] [Abstract][Full Text] [Related]
10. Ascorbic acid decreases the antifungal effect of fluconazole in the treatment of candidiasis.
Wang Y; Jia XM; Jia JH; Li MB; Cao YY; Gao PH; Liao WQ; Cao YB; Jiang YY
Clin Exp Pharmacol Physiol; 2009 Oct; 36(10):e40-6. PubMed ID: 19413603
[TBL] [Abstract][Full Text] [Related]
11. Fluconazole distribution to the brain: a crossover study in freely-moving rats using in vivo microdialysis.
Yang H; Wang Q; Elmquist WF
Pharm Res; 1996 Oct; 13(10):1570-5. PubMed ID: 8899853
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis.
Wring SA; Randolph R; Park S; Abruzzo G; Chen Q; Flattery A; Garrett G; Peel M; Outcalt R; Powell K; Trucksis M; Angulo D; Borroto-Esoda K
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137806
[TBL] [Abstract][Full Text] [Related]
13. Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans.
Andes D; Forrest A; Lepak A; Nett J; Marchillo K; Lincoln L
Antimicrob Agents Chemother; 2006 Jul; 50(7):2374-83. PubMed ID: 16801415
[TBL] [Abstract][Full Text] [Related]
14. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.
Andes D; Marchillo K; Stamstad T; Conklin R
Antimicrob Agents Chemother; 2003 Oct; 47(10):3165-9. PubMed ID: 14506026
[TBL] [Abstract][Full Text] [Related]
15. Demonstration of Therapeutic Equivalence of Fluconazole Generic Products in the Neutropenic Mouse Model of Disseminated Candidiasis.
Gonzalez JM; Rodriguez CA; Zuluaga AF; Agudelo M; Vesga O
PLoS One; 2015; 10(11):e0141872. PubMed ID: 26536105
[TBL] [Abstract][Full Text] [Related]
16. Does the Anesthetic Urethane Influence the Pharmacokinetics of Antifungal Drugs? A Population Pharmacokinetic Investigation in Rats.
Azeredo FJ; Hass SE; Sansone P; Derendorf H; Costa TD; De Araujo BV
J Pharm Sci; 2015 Oct; 104(10):3314-8. PubMed ID: 26087701
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of PLD-118, a novel inhibitor of candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans.
Petraitis V; Petraitiene R; Kelaher AM; Sarafandi AA; Sein T; Mickiene D; Bacher J; Groll AH; Walsh TJ
Antimicrob Agents Chemother; 2004 Oct; 48(10):3959-67. PubMed ID: 15388459
[TBL] [Abstract][Full Text] [Related]
18. Microdialysis as a tool to determine free kidney levels of voriconazole in rodents: a model to study the technique feasibility for a moderately lipophilic drug.
Araujo BV; Silva CF; Haas SE; Dalla Costa T
J Pharm Biomed Anal; 2008 Aug; 47(4-5):876-81. PubMed ID: 18395391
[TBL] [Abstract][Full Text] [Related]
19. Quercetin Assists Fluconazole to Inhibit Biofilm Formations of Fluconazole-Resistant Candida Albicans in In Vitro and In Vivo Antifungal Managements of Vulvovaginal Candidiasis.
Gao M; Wang H; Zhu L
Cell Physiol Biochem; 2016; 40(3-4):727-742. PubMed ID: 27915337
[TBL] [Abstract][Full Text] [Related]
20. Antifungal activities of R-135853, a sordarin derivative, in experimental candidiasis in mice.
Kamai Y; Kakuta M; Shibayama T; Fukuoka T; Kuwahara S
Antimicrob Agents Chemother; 2005 Jan; 49(1):52-6. PubMed ID: 15616275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
